References
- Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: The J-RAPID randomized, placebo-controlled trial. Mod Rheumatol. 2013; (epub ahead of print) doi:10.3109/14397595.2013.864224.
- Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial. Mod Rheumatol. 2013; (epub ahead of print) doi:10.3109/14397595.2013.843764.
- Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, et al. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Mod Rheumatol. 2014; (epub ahead of print) doi: 10.3109/14397595.2014.881709.
- Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, et al. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Mod Rheumatol. 2013; (epub ahead of print) doi: 10.3109/14397595.2013.865822.
- Keystone EC, Curtis JR, Fleischmann RM, Furst DE, Khann D, Smolen JS, et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol. 2011;38(6):990–6; doi:10.3899/jrheum.100935
- van del Heijde D, Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: A post-hoc analysis of the RAPID 1 trial. Rheumatol.2012;39(7):1326–33; doi:10.3899/jrheum.111171
- Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. published online Octorber25, 2013. doi: 10.1136/annrheumdis-2013-204573.
- Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–39. doi:10.1002/acr.21641.
- Smolen JS, Aletaha D, Fijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7; doi:10.1136/ard.2009.123919
- Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007; 56(10):3226–35.
- van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34–40.
- Welsing PMA, van Riel PLCM. The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol. 2004;69:14–21.
- Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. Arthritis Rheum. 2013;65(Suppl.10): S989–S989.
- Weinblatt M, Fleishmann R, Davis O, Luijtens K, van del Heijde D. Timing and magnitude of initial response to certolizumab pegol in a broad population of patients with active rheumatoid arthritis predicts likelihood of LDA at week 28. Ann Rheum Dis. 2012;71(suppl3):520.